[Federal Register Volume 79, Number 236 (Tuesday, December 9, 2014)]
[Notices]
[Pages 73091-73092]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2014-28749]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive Evaluation Option License 
Agreement: A3 Adenosine Receptor (A3AR) Agonists as an Orally-
Administered Analgesic for Treatment of Chronic Neuropathic Pain

AGENCY: National Institutes of Health, HHS

ACTION: Notice

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of a Start-Up Exclusive 
Evaluation Option License Agreement to BioIntervene, Inc., a company 
having a place of business in Saint Louis, Missouri to practice the 
inventions embodied in the following patent applications and patents:
    1. U.S. Patent 8,735,407, issued May 27, 2014, titled ``Purine 
Derivatives As A3 Adenosine Receptor-Selective Agonists'' [HHS Ref. No. 
E-140-2008/0-US-06];
    2. European Patent Application 09728154.7, filed March 24, 2009, 
titled ``Purine Derivatives As A3 Adenosine Receptor-Selective 
Agonists'' [HHS Ref. No. E-140-2008/0-EP-05];
    3. Canadian Patent Application 2720037, filed March 24, 2009, 
titled ``Purine Derivatives As A3 Adenosine Receptor-Selective 
Agonists'' [HHS Ref. No. E-140-2008/0-CA-04];

[[Page 73092]]

    4. Australian Patent 2009231978, issued February 20, 2014, titled 
``Purine Derivatives As A3 Adenosine Receptor-Selective Agonists'' [HHS 
Ref. No. E-140-2008/0-AU-03];
    5. U.S. Patent Application 13/371,081, filed February 10, 2012, 
titled ``A3 Adenosine Receptor Agonists And Antagonists'' [HHS Ref. No. 
E-140-2008/1-US-01];
    6. U.S. Provisional Application 61/909,742, filed November 27, 
2013, titled ``A3 Adenosine Receptor Agonists'' [HHS Ref. No. E-742-
2013/0-US-01]; and
    7. U.S. Provisional Application 62/033,723, filed August 6, 2014, 
titled ``A3 Adenosine Receptor Agonists'' [HHS Ref. No. E-210-2014/0-
US-01].
    The patent rights in these inventions either have been assigned to 
the Government of the United States of America, or have been granted 
exclusive rights to the Government of the United States of America. The 
territory of the prospective Start-up Exclusive Evaluation Option 
License Agreement may be worldwide, and the field of use may be limited 
to: ``The use of an A3 Adenosine Receptor (A3AR) agonist as an orally-
administered analgesic, either as monotherapy or as an add-on 
analgesic, for treatment of chronic neuropathic pain conditions''.
    Upon the expiration or termination of the Start-up Exclusive 
Evaluation Option License Agreement, BioIntervene will have the 
exclusive right to execute a Start-up Exclusive Patent License 
Agreement which will supersede and replace the Start-up Exclusive 
Evaluation Option License Agreement, with no greater field of use and 
territory than granted in the Start-up Exclusive Evaluation Option 
License Agreement.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
December 24, 2014 will be considered.

ADDRESSES: Requests for copies of the patents, patent applications, 
inquiries, comments, and other materials relating to the contemplated 
Start-Up Exclusive Evaluation Option License Agreement should be 
directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting 
Manager, Office of Technology Transfer, National Institutes of Health, 
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; 
Telephone: (301) 594-6565; Facsimile: (301) 402-0220; Email: 
[email protected]. A signed confidentiality nondisclosure agreement 
will be required to receive copies of any patent applications that have 
not been published or issued by the United States Patent and Trademark 
Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: The subject inventions describe selective A3 
Adenosine Receptor (A3AR) agonists, and their in vivo activity reducing 
or preventing development of chronic neuropathic pain in an animal 
model. The A3AR subtype was linked with helping protect the heart from 
ischemia, controlling inflammation, and regulating cell proliferation. 
The compounds claimed are consistently highly selective and have 
smaller molecular weight, thus can offer greater oral bioavailability. 
Hence, the subject inventions may provide a new treatment for chronic 
neuropathic pain.
    The prospective Start-up Exclusive Evaluation Option License 
Agreement and a subsequent Start-up Exclusive Patent License Agreement 
may be granted unless the NIH receives written evidence and argument, 
within fifteen (15) days from the date of this published notice, that 
establishes that the grant of the contemplated Start-up Exclusive 
Evaluation Option License Agreement would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Start-Up Exclusive Evaluation Option 
License Agreement. Comments and objections submitted in response to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: December 3, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2014-28749 Filed 12-8-14; 8:45 am]
BILLING CODE 4140-01-P